Novo Nordisk has seen its share price come under pressure, and the question for you now is whether the current valuation is still supported by the earnings power of the business. With sentiment shifting around diabetes and obesity treatments, the key issue is how much of Novo Nordisk's profit potential is already built into today's price.
-
Over the past 3 years, Novo Nordisk's stock has fallen 59.6%, which puts the focus squarely on whether the earnings profile justifies where the shares trade today.
-
Fresh trial data from Eli Lilly showing retatrutide outperforming Ozempic, alongside regulatory progress on rival GLP-1 treatments, can influence how investors think about Novo Nordisk's future earnings durability and pricing power in its core franchises.
-
The analysts covering Novo Nordisk have run their own numbers. See what analysts think Novo Nordisk's shares could be worth .
The issue now is whether Novo Nordisk's current share price is reasonable when set against the earnings that the business generates today and what investors expect it to produce in the future.
If you want more context around Novo Nordisk's recent share price slide and earnings debate, it can help to line it up against other 123 healthcare AI stocks .
Does Novo Nordisk Look Undervalued on Earnings?
The P/E ratio suits Novo Nordisk because earnings are the main driver investors watch for large, established drug makers. On this measure, Novo Nordisk trades on about 9.7x earnings, while the wider Pharmaceuticals sector averages roughly 20.6x and peers cluster closer to 33.9x. That is a sizeable gap, which points to the stock changing hands at a lower earnings multiple than many comparable healthcare groups.
The fair P/E that accounts for Novo Nordisk's margins, size and risk profile sits above the current 9.7x level, which signals the shares screen as undervalued on this framework. Despite recent trial results from Eli Lilly putting more pressure on sentiment around Ozempic and related therapies, the present multiple still prices Novo Nordisk at a discount to both its sector and peer set. Explore the numbers behind Novo Nordisk's P/E valuation .
The Novo Nordisk Narrative: What Would Justify Today's Price?
Novo Nordisk's Simply Wall St Narratives pick up where the P/E puzzle leaves off. They explain which paths for future growth, margins and earnings would need to hold for the stock to be worth materially more, or less, than today's price. Each narrative ties a fair value estimate to a specific mix of potential catalysts and risks, so you can track over time which version of Novo Nordisk's story is actually unfolding on the Community page.
The Simply Wall St community is split on Novo Nordisk, with one camp seeing deep value and the other arguing expectations already look full.
Bull case: 70% undervalued
"With high barriers to entry, a booming market for obesity treatment, and a pipeline that keeps expanding, Novo Nordisk's future looks remarkably secure…"
Discover why this Narrative puts Novo Nordisk at 70% undervalued .
Bear case: 26% overvalued
"The numbers imply that Novo Nordisk's current share price already reflects mid single digit revenue growth through 2030, with at least five multi-blockbuster launches and more than DKK 150 billion of annual pipeline sales by 2035…"
Explore why this Narrative puts Novo Nordisk at 26% overvalued .
Novo Nordisk: why who runs it can matter as much as what you pay
Price only tells part of the story for Novo Nordisk, because the people steering the business and how they are rewarded can shape risk, returns and decision making over years to come. See who runs Novo Nordisk and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
